Denali Therapeutics is moving into the most delicate phase of its evolution: from a blood–brain-barrier platform story to a commercial-stage rare-disease company. The centre of gravity is tividenofusp alfa (DNL310), a TransportVehicle-enabled enzyme replacement therapy for Hunter syndrome (MPS II) designed to address both systemic and central nervous system manifestations, something that current standard ERTs cannot do.

TuHURA announces that Kintara’s REM-001 trial in metastatic cutaneous breast cancer has met its primary safety endpoint in ten patients with early signs of clinical efficacy. This triggers the contractual milestone under the Kintara CVR Agreement and unlocks the distribution of 1,539,958 HURA shares to legacy Kintara shareholders holding CVRs.

Maze trades as a high-expectations play on APOL1-mediated kidney disease: the stock has rerated into a roughly mid-cap valuation on the back of a very strong balance sheet and the upcoming proof-of-concept data from the HORIZON Phase 2 trial in a broad AMKD population. The key tension now is simple: can the first substantive MZE829 dataset justify how far the share price has already come.

The FDA has sent a Complete Response Letter (CRL) for RGX-121 (clemidsogene lanparvovec) in MPS II, rejecting the BLA under the accelerated approval pathway and questioning the external control, the neuronopathic eligibility criteria and the CSF HS D2S6 biomarker. Management plans a Type A meeting and aims to resubmit, but the ultra-rare MPS II path is now longer and more complex, against a backdrop of recent clinical holds on the company’s ultra-rare MPS programs.

Ensysce Biosciences has provided a new operational update on its pivotal Phase 3 trial PF614-301, which evaluates PF614, a next-generation oxycodone prodrug, in patients with moderate to severe acute pain following abdominoplasty surgery. The company reports that the study has now enrolled 50% of the subjects targeted for the planned interim review, a meaningful operational milestone for a small clinical-stage pain company trying to move an abuse- and overdose-resistant opioid toward the market.

Potential resubmission of the supplemental BLA for BCG-unresponsive papillary NMIBC following the January 20 FDA meeting. The company committed to deliver additional analyses within 30 days, without new clinical trials. If the resubmission is accepted, the review clock could define the next major run-up window.

Biofrontera (BFRI) – Positive Phase 3 trunk/extremities data for Ameluz PDT, sharp micro-cap sell-off
Biofrontera reports that its Phase 3 study of Ameluz® PDT for actinic keratoses on the extremities, neck and trunk met the primary endpoint, strengthening the case for a 2026 sNDA – but the stock trades lower intraday, reminding investors how noisy tiny-cap price action can be.

Protara Therapeutics (TARA) — TARA-002 Phase 2 NMIBC catalyst at the end of February 2026
Protara Therapeutics is a small-cap biotech that has quietly moved from “option on survival” to a fully funded late-stage story built around a single, high-leverage asset: TARA-002. The drug is a TLR2/NOD2 agonist derived from the same cell bank as the long-used immunotherapy OK-432 (Picibanil) and is being developed both for non-muscle invasive bladder cancer (NMIBC) and for pediatric lymphatic malformations. The near-term catalyst now staring at the tape is an updated Phase 2 read-out in BCG-unresponsive NMIBC that will be presented on 27 February 2026 and that the company itself frames as aligned with the registrational pathway for this setting.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).

Clinical-stage oncology company focused on bispecific antibodies that couple angiogenesis and immune modulation.